Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Endocrinology
•
Lipid Disorders
•
Nutrition and Obesity
Should biomarkers of insulin resistance (HOMA-IR) be used to guide medical therapy in healthy patients at higher risk for diabetes based on ethnicity and family history?
Related Questions
Is intermittent fasting effective for weight loss?
How does the TACTiC trial's success with a web app for statin self-management influence your stance on nonprescription statins for primary prevention amidst statin underuse?
Should Orlistat be considered in the management of hypertriglyceridemia?
Should insulin be started early (prior to optimization of other anti-hyperglycemic medications) in patients with mild-to-moderate diabetes and hypertriglyceridemia refractory to statin and fibrates?
Should weight loss medications be used in women who are gaining excessive weight during pregnancy?
Do you use the homeostatic model assessment (HOMA) to assess for insulin resistance and change your clinical management of patients?
Should metformin be used in women with PCOS for weight loss?
Should patients with mild subclinical hypothyroidism (TSH < 10 mIU/L) be treated with thyroid hormone replacement to improve their lipid profile?
Should lipid lowering therapy be started in patients with isolated elevation in lipoprotein (a) and minimal cardiovascular risk?
Should low-intensity statins be favored to minimize the risk of diabetes onset while still offering cardiovascular benefit for patients with prediabetes where a statin is indicated?
